{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:58:57Z","timestamp":1790881137834,"version":"4.1.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Psoriasis is a chronic inflammatory skin condition. It is being increasingly treated with biologic agents targeting specific immune pathways. These treatments target specific immune system pathways involved in the disease. Drug survival (how long patients remain on a given treatment) is a key measure of long-term effectiveness and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To analyse the drug survival rates of approved biologics for psoriasis using Danish nationwide register-based data from 2018 to 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study used a nationwide register-based cohort of patients diagnosed with psoriasis in Denmark who were treated with biologics between 2018 and 2023. Patients were stratified by the presence or absence of psoriatic arthritis (PsA). Drug survival was assessed using Kaplan\u2013Meier curves, and the rate of discontinuation was analysed using Cox proportional hazards regression models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the biologics studied, infliximab had the highest 1-year drug survival (49%), followed by ustekinumab (42%). Bimekizumab, the most recently introduced biologic in Denmark, had a 19% drug survival rate after 349 days. Ustekinumab had longer persistence in patients who only had psoriasis, but the drug survival rate was reduced in patients with PsA. In contrast, infliximab maintained robust performance across both patient groups, with a significantly lower risk of discontinuation compared with ustekinumab (hazard ratio 0.59, 95% confidence intervals 0.53\u20130.67), particularly in patients with PsA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Drug survival differed across biologic treatments and according to PsA status. Infliximab had higher overall drug survival, particularly in patients with PsA. Ustekinumab had greater treatment persistence in patients without PsA but lower drug survival in those with PsA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/skinhd\/vzag054","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T12:20:03Z","timestamp":1773404403000},"page":"485-495","source":"Crossref","is-referenced-by-count":1,"title":["Drug survival of biologic treatments for psoriasis and psoriatic arthritis in Denmark, 2018\u201323: a nationwide register\u2013based cohort study"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7150-4685","authenticated-orcid":false,"given":"Sejun","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Paediatrics and Adolescents Medicine, Rigshospitalet , Copenhagen ,","place":["Denmark"]},{"name":"Mary Elizabeth\u2019s Hospital\u2019s Data Powerhouse, Rigshospitalet , Copenhagen ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Jensen","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Adolescents Medicine, Rigshospitalet , Copenhagen ,","place":["Denmark"]},{"name":"Mary Elizabeth\u2019s Hospital\u2019s Data Powerhouse, Rigshospitalet , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Egeberg","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen ,","place":["Denmark"]},{"name":"Department of Dermatology, Bispebjerg Hospital , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1569-153X","authenticated-orcid":false,"given":"Lone Graff","family":"Stensballe","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Adolescents Medicine, Rigshospitalet , Copenhagen ,","place":["Denmark"]},{"name":"Mary Elizabeth\u2019s Hospital\u2019s Data Powerhouse, Rigshospitalet , Copenhagen ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"2026073105092756300_vzag054-B1","author":"World Health Organization (WHO)"},{"key":"2026073105092756300_vzag054-B2","doi-asserted-by":"crossref","first-page":"e028116","DOI":"10.1136\/bmjopen-2018-028116","article-title":"Prevalence and characteristics of psoriasis in Denmark: findings from the Danish skin cohort","volume":"9","author":"Egeberg","year":"2019","journal-title":"BMJ Open"},{"key":"2026073105092756300_vzag054-B3","author":"Statistics Denmark"},{"key":"2026073105092756300_vzag054-B4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/intimm\/dxv063","article-title":"Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases","volume":"28","author":"Lai","year":"2016","journal-title":"Int Immunol"},{"key":"2026073105092756300_vzag054-B5","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23\u2013IL-17 immune axis: from mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"2026073105092756300_vzag054-B6","doi-asserted-by":"crossref","first-page":"e20202191","DOI":"10.1084\/jem.20202191","article-title":"The metabolism-modulating activity of IL-17 signaling in health and disease","volume":"218","author":"Bechara","year":"2021","journal-title":"J Exp Med"},{"key":"2026073105092756300_vzag054-B7","first-page":"111","article-title":"Biologics in the management of psoriasis","volume":"2","author":"Bahner","year":"2009","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2026073105092756300_vzag054-B8","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1080\/21645515.2017.1356498","article-title":"Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis","volume":"13","author":"Jeon","year":"2017","journal-title":"Hum Vaccines Immunother"},{"key":"2026073105092756300_vzag054-B9","doi-asserted-by":"crossref","first-page":"1341708","DOI":"10.3389\/fimmu.2023.1341708","article-title":"Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses \u2013 IL PSO (Italian landscape psoriasis)","volume":"14","author":"Gargiulo","year":"2024","journal-title":"Front Immunol"},{"key":"2026073105092756300_vzag054-B10","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/jdv.19584","article-title":"Drug survival of biologic therapies for palmoplantar pustulosis: a nationwide study","volume":"38","author":"Bertelsen","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026073105092756300_vzag054-B11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000488586","article-title":"Effectiveness end points in real-world studies on biological therapies in psoriasis: systematic review with focus on drug survival","volume":"234","author":"Costanzo","year":"2018","journal-title":"Dermatology"},{"key":"2026073105092756300_vzag054-B12","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/bjd.16102","article-title":"Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis","volume":"178","author":"Egeberg","year":"2018","journal-title":"Br J Dermatol"},{"key":"2026073105092756300_vzag054-B13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/1403494811401482","article-title":"The Danish National Patient Register","volume":"39","author":"Lynge","year":"2011","journal-title":"Scand J Public Health"},{"key":"2026073105092756300_vzag054-B14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/1403494810394717","article-title":"The Danish national prescription registry","volume":"39","author":"Wallach Kildemoes","year":"2011","journal-title":"Scand J Public Health"},{"key":"2026073105092756300_vzag054-B15","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/CLEP.S91125","article-title":"The Danish National Patient Registry: a review of content, data quality, and research potential","volume":"7","author":"Schmidt","year":"2015","journal-title":"Clin Epidemiol"},{"key":"2026073105092756300_vzag054-B16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1403494810387965","article-title":"The Danish civil registration system","volume":"39","author":"Pedersen","year":"2011","journal-title":"Scand J Public Health"},{"key":"2026073105092756300_vzag054-B17","volume-title":"International Statistical Classification of Diseases and Related Health Problems 10th Revision","author":"World Health Organization (WHO)","year":"2016"},{"key":"2026073105092756300_vzag054-B18","author":"Norwegian Institute of Public Health"},{"key":"2026073105092756300_vzag054-B19","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.2340\/00015555-3278","article-title":"Validation of psoriasis diagnoses in the Danish National Patient Register","volume":"99","author":"Loft","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"2026073105092756300_vzag054-B20","doi-asserted-by":"crossref","first-page":"e70064","DOI":"10.1002\/pds.70064","article-title":"Post-marketing safety of ustekinumab based on 14-year follow-up in Danish national patient data","volume":"33","author":"Kim","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026073105092756300_vzag054-B21","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"2026073105092756300_vzag054-B22","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/jamadermatol.2024.1677","article-title":"Clinical characteristics associated with response to biologics in the treatment of psoriasis: a meta-analysis","volume":"160","author":"Hjort","year":"2024","journal-title":"JAMA Dermatol"},{"key":"2026073105092756300_vzag054-B23","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the Tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"J Open Source Softw"},{"key":"2026073105092756300_vzag054-B24","author":"Wickham"},{"key":"2026073105092756300_vzag054-B25","author":"Therneau"},{"key":"2026073105092756300_vzag054-B26","author":"Wickham"},{"key":"2026073105092756300_vzag054-B27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/14712598.2020.1812576","article-title":"Anti-tumor necrosis factor agents in psoriasis: addressing key challenges using biosimilars","volume":"21","author":"Prignano","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"2026073105092756300_vzag054-B28","doi-asserted-by":"crossref","first-page":"e70050","DOI":"10.1002\/pds.70050","article-title":"Biologics used for psoriasis: a drug utilization study based on two nationwide Danish data sources","volume":"33","author":"Engel-Andreasen","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026073105092756300_vzag054-B29","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00228-019-02765-3","article-title":"The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars","volume":"76","author":"Jensen","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"2026073105092756300_vzag054-B30","doi-asserted-by":"crossref","first-page":"e002560","DOI":"10.1136\/rmdopen-2022-002560","article-title":"Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry","volume":"8","author":"Nabi","year":"2022","journal-title":"RMD Open"},{"key":"2026073105092756300_vzag054-B31","doi-asserted-by":"crossref","first-page":"e001016","DOI":"10.1136\/rmdopen-2019-001016","article-title":"Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis","volume":"5","author":"Glintborg","year":"2019","journal-title":"RMD Open"},{"key":"2026073105092756300_vzag054-B32","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/jdv.14200","article-title":"Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis\u2014nationwide results from the DERMBIO registry","volume":"31","author":"Egeberg","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026073105092756300_vzag054-B33","author":"Danish Medicines Council"},{"key":"2026073105092756300_vzag054-B34","first-page":"34","article-title":"Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment","volume":"22","author":"Mastorino","year":"2024","journal-title":"J Dtsch Dermatol Ges"},{"key":"2026073105092756300_vzag054-B35","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40265-024-02028-1","article-title":"Drug survival of IL-17 and IL-23 inhibitors for psoriasis: a systematic review and meta-analysis","volume":"84","author":"Thomas","year":"2024","journal-title":"Drugs"},{"key":"2026073105092756300_vzag054-B36","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1111\/jdv.20739","article-title":"Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: a British Association of Dermatologists Biologics and Immunomodulators Register cohort study","volume":"39","author":"Motedayen Aval","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026073105092756300_vzag054-B37","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-92938-1","volume-title":"Biologic Therapy for Psoriasis: Cutting Edge Treatment Principles","author":"Brownstone","year":"2022"},{"key":"2026073105092756300_vzag054-B38","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1111\/jdv.13634","article-title":"Psoriasis registries worldwide: systematic overview on registry publications","volume":"30","author":"Eissing","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026073105092756300_vzag054-B39","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/jamadermatol.2019.0001","article-title":"Association of ustekinumab vs TNF inhibitor therapy with risk of atrial fibrillation and cardiovascular events in patients with psoriasis or psoriatic arthritis","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2026073105092756300_vzag054-B40","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/24755303211047479","article-title":"TNF-alpha inhibitors and ustekinumab for the treatment of psoriasis: therapeutic utility in the era of IL-17 and IL-23 inhibitors","volume":"7","author":"Hong","year":"2022","journal-title":"J Psoriasis Psoriatic Arthritis"}],"container-title":["Skin Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/6\/4\/485\/68207659\/vzag054.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/6\/4\/485\/68207659\/vzag054.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:09:39Z","timestamp":1785488979000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/skinhd\/article\/6\/4\/485\/8666943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,5,4]]},"published-print":{"date-parts":[[2026,7,31]]}},"URL":"https:\/\/doi.org\/10.1093\/skinhd\/vzag054","relation":{},"ISSN":["2690-442X"],"issn-type":[{"value":"2690-442X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,5,4]]}}}